Form 4 for TARS Tarsus Pharmaceuticals, Inc.
Accepted 2026-03-17 00:00:00 ET · period of report 2026-03-15 · accession 0001842190-26-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-17 | 2026-03-15 | TARS | Lin Elizabeth Yeu | Chief Medical Off | M - OptEx | — | +2,511 | 24.5K | +11% | — |
| D | 2026-03-17 | 2026-03-15 | TARS | Lin Elizabeth Yeu | Chief Medical Off | M - OptEx | $0.00 | -2,511 | 7,534 | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-15 | M | A | 2,511 | — | 24,452 | D | — | — | (F1) The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). |
| 2 | Derivative | Restricted Stock Units | 2026-03-15 | M | D | 2,511 | $0.00 | 7,534 | D | — · — to — | 2,511 Common Stock | (F2) Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock. (F3) RSUs granted on March 5, 2025, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service. |